Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V (March 2008). "Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review". Hum Exp Toxicol. 27 (3): 181–194. Bibcode:2008HETox..27..181M. doi:10.1177/0960327107087802. PMID18650249.
Soriano-García M, Walls F, Rodríguez A, Celis IL (1988). "Crystal and molecular structure of ibogamine: An alkaloid from Stemmadenia galeottiana". Journal of Crystallographic and Spectroscopic Research. 18 (2): 197–206. Bibcode:1988JCCry..18..197S. doi:10.1007/BF01181911. S2CID97519993.
O'Hearn E, Molliver ME (July 1993). "Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline". Neuroscience. 55 (2): 303–10. doi:10.1016/0306-4522(93)90500-f. PMID8377927. S2CID25273690.
Krengel F, Mijangos MV, Reyes-Lezama M, Reyes-Chilpa R (July 2019). "Extraction and Conversion Studies of the Antiaddictive Alkaloids Coronaridine, Ibogamine, Voacangine, and Ibogaine from Two Mexican Tabernaemontana Species (Apocynaceae)". Chemistry & Biodiversity. 16 (7): e1900175. doi:10.1002/cbdv.201900175. ISSN1612-1872. OCLC8185274820. PMID31095891. S2CID157058497.
Pace CJ, Glick SD, Maisonneuve IM, He LW, Jokiel PA, Kuehne ME, et al. (May 2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration". European Journal of Pharmacology. 492 (2–3): 159–67. doi:10.1016/j.ejphar.2004.03.062. ISSN0014-2999. OCLC110898054. PMID15178360.
Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson D, Keller RW, et al. (September 1994). "Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum". Brain Research. 657 (1–2): 14–22. doi:10.1016/0006-8993(94)90948-2. ISSN0006-8993. OCLC4923262393. PMID7820611. S2CID1940631.
US patent 2813873, Morrice-Marie Janot & Robert Goutarel, "Derivatives of the ibogaine alkaloids", issued 19 November 1957, assigned to Les Laboratoires Gobey
ethz.ch
e-collection.ethbib.ethz.ch
Frauenfelder C (1999). Ph.D. (Thesis). p. 24. Archived from the original(PDF) on 29 July 2012.
"The 2007 FFF Winners". San Francisco Frozen Film Festival (SFFFF). 13 July 2007. Facing the Habit (WORLD PREMIERE). Retrieved 2 September 2024.
harvard.edu
ui.adsabs.harvard.edu
Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V (March 2008). "Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review". Hum Exp Toxicol. 27 (3): 181–194. Bibcode:2008HETox..27..181M. doi:10.1177/0960327107087802. PMID18650249.
Soriano-García M, Walls F, Rodríguez A, Celis IL (1988). "Crystal and molecular structure of ibogamine: An alkaloid from Stemmadenia galeottiana". Journal of Crystallographic and Spectroscopic Research. 18 (2): 197–206. Bibcode:1988JCCry..18..197S. doi:10.1007/BF01181911. S2CID97519993.
Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V (March 2008). "Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review". Hum Exp Toxicol. 27 (3): 181–194. Bibcode:2008HETox..27..181M. doi:10.1177/0960327107087802. PMID18650249.
O'Hearn E, Molliver ME (July 1993). "Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline". Neuroscience. 55 (2): 303–10. doi:10.1016/0306-4522(93)90500-f. PMID8377927. S2CID25273690.
Krengel F, Mijangos MV, Reyes-Lezama M, Reyes-Chilpa R (July 2019). "Extraction and Conversion Studies of the Antiaddictive Alkaloids Coronaridine, Ibogamine, Voacangine, and Ibogaine from Two Mexican Tabernaemontana Species (Apocynaceae)". Chemistry & Biodiversity. 16 (7): e1900175. doi:10.1002/cbdv.201900175. ISSN1612-1872. OCLC8185274820. PMID31095891. S2CID157058497.
Pace CJ, Glick SD, Maisonneuve IM, He LW, Jokiel PA, Kuehne ME, et al. (May 2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration". European Journal of Pharmacology. 492 (2–3): 159–67. doi:10.1016/j.ejphar.2004.03.062. ISSN0014-2999. OCLC110898054. PMID15178360.
Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson D, Keller RW, et al. (September 1994). "Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum". Brain Research. 657 (1–2): 14–22. doi:10.1016/0006-8993(94)90948-2. ISSN0006-8993. OCLC4923262393. PMID7820611. S2CID1940631.
Dzoljic ED, Kaplan CD, Dzoljic MR (1988). "Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats". Archives Internationales de Pharmacodynamie et de Therapie. 294: 64–70. ISSN0003-9780. OCLC115924585. PMID3233054.
Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JN (April 1991). "Effects and aftereffects of ibogaine on morphine self-administration in rats". European Journal of Pharmacology. 195 (3): 341–5. doi:10.1016/0014-2999(91)90474-5. ISSN0014-2999. OCLC121337019. PMID1868880.
Soriano-García M, Walls F, Rodríguez A, Celis IL (1988). "Crystal and molecular structure of ibogamine: An alkaloid from Stemmadenia galeottiana". Journal of Crystallographic and Spectroscopic Research. 18 (2): 197–206. Bibcode:1988JCCry..18..197S. doi:10.1007/BF01181911. S2CID97519993.
O'Hearn E, Molliver ME (July 1993). "Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline". Neuroscience. 55 (2): 303–10. doi:10.1016/0306-4522(93)90500-f. PMID8377927. S2CID25273690.
Krengel F, Mijangos MV, Reyes-Lezama M, Reyes-Chilpa R (July 2019). "Extraction and Conversion Studies of the Antiaddictive Alkaloids Coronaridine, Ibogamine, Voacangine, and Ibogaine from Two Mexican Tabernaemontana Species (Apocynaceae)". Chemistry & Biodiversity. 16 (7): e1900175. doi:10.1002/cbdv.201900175. ISSN1612-1872. OCLC8185274820. PMID31095891. S2CID157058497.
Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson D, Keller RW, et al. (September 1994). "Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum". Brain Research. 657 (1–2): 14–22. doi:10.1016/0006-8993(94)90948-2. ISSN0006-8993. OCLC4923262393. PMID7820611. S2CID1940631.
Krengel F, Mijangos MV, Reyes-Lezama M, Reyes-Chilpa R (July 2019). "Extraction and Conversion Studies of the Antiaddictive Alkaloids Coronaridine, Ibogamine, Voacangine, and Ibogaine from Two Mexican Tabernaemontana Species (Apocynaceae)". Chemistry & Biodiversity. 16 (7): e1900175. doi:10.1002/cbdv.201900175. ISSN1612-1872. OCLC8185274820. PMID31095891. S2CID157058497.
Pace CJ, Glick SD, Maisonneuve IM, He LW, Jokiel PA, Kuehne ME, et al. (May 2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration". European Journal of Pharmacology. 492 (2–3): 159–67. doi:10.1016/j.ejphar.2004.03.062. ISSN0014-2999. OCLC110898054. PMID15178360.
Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson D, Keller RW, et al. (September 1994). "Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum". Brain Research. 657 (1–2): 14–22. doi:10.1016/0006-8993(94)90948-2. ISSN0006-8993. OCLC4923262393. PMID7820611. S2CID1940631.
Dzoljic ED, Kaplan CD, Dzoljic MR (1988). "Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats". Archives Internationales de Pharmacodynamie et de Therapie. 294: 64–70. ISSN0003-9780. OCLC115924585. PMID3233054.
Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JN (April 1991). "Effects and aftereffects of ibogaine on morphine self-administration in rats". European Journal of Pharmacology. 195 (3): 341–5. doi:10.1016/0014-2999(91)90474-5. ISSN0014-2999. OCLC121337019. PMID1868880.